Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABVC BioPharmaABVC -4.48%17 3-Year EBITDA Growth Rate is 57.40% as of Mar. 2026, which is 33% above its 10-year median of 43.10. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,137 Biotechnology companies, ABVC BioPharma ranks better than 89.09% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 57.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 46.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ABVC BioPharma was 90.60% per year. The lowest was -108.20% per year. And the median was 43.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ABVC BioPharma 3-Year EBITDA Growth Rate Related Terms
ABVC vs GRCE, ELOX, INMB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, ABVC BioPharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 57.40% mean?
ABVC BioPharma (ABVC) has a 3-Year EBITDA Growth Rate of 57.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ABVC BioPharma and its competitors. This is 33% above median its historical median of 43.10. According to the industry distribution chart, ABVC BioPharma ranks #124 out of 1137 companies in the Biotechnology industry, placing it in the top 10.9%.
Is ABVC BioPharma's 3-Year EBITDA Growth Rate too high?
ABVC BioPharma's current 3-Year EBITDA Growth Rate of 57.40% is 33% above median its 10-year median of 43.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. ABVC BioPharma's value of 57.40% is 285.2% above this industry median. Based on the distribution chart, ABVC BioPharma ranks #124 out of 1137 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's 3-Year EBITDA Growth Rate compare to GRCE and ELOX?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #124 out of 1137 companies for 3-Year EBITDA Growth Rate. This places ABVC BioPharma in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. ABVC BioPharma's value of 57.40% is 285.2% above this benchmark. While the company's 10-year median is 43.10 vs. the industry median of 14.90, ABVC BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABVC BioPharma's current 3-Year EBITDA Growth Rate of 57.40% is 285.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ABVC BioPharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABVC BioPharma's current 3-Year EBITDA Growth Rate is 57.40%, which is 33% above median its own 10-year median of 43.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.28 — trading 47.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 57.40%, which is 33% above median its 10-year median of 43.10 and 285.2% above the Biotechnology industry median of 14.90. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current 3-Year EBITDA Growth Rate is 57.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $1.28 is trading 47.1% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
3-Year EBITDA Growth Rate: 57.40% (33% above median its 10-year median of 43.10)
GF Value™: $0.87 vs. price of $1.28 (47.1% above fair value)
Industry Position: 285.2% above the Biotechnology median (#124 of 1137)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
